Director Jane Henderson of Lycia Therapeutics, Inc. filed a Form 4 on October 26, 2026, reporting the acquisition of two stock option grants covering a combined 77,666 shares of common stock, with transaction dates of August 11, 2026, and October 22, 2026.

Key Highlights

  • Reporting person: Jane Henderson, identified as a Director of Lycia Therapeutics, Inc. (NASDAQ:LYCA).
  • First option grant: 57,666 stock options acquired on August 11, 2026, at an exercise price of $3.70, expiring August 10, 2036.
  • Second option grant: 20,000 stock options acquired on October 22, 2026, at an exercise price of $18.00, expiring October 21, 2036.
  • Combined derivative holdings: 77,666 stock options beneficially owned following both reported transactions, all held directly.
  • Price of derivative securities: Both grants were acquired at a price of $0, according to the filing.
  • Pre-IPO disclosure: The August 11, 2026, transaction "occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering," and is reported pursuant to Rule 16a-2(a).

Two Stock Option Grants Awarded to Lycia Therapeutics Director Henderson

According to the Form 4 filed with the SEC on October 26, 2026, Jane Henderson, a director of Lycia Therapeutics, Inc., received two separate stock option grants in the form of rights to buy common stock. The first grant, dated August 11, 2026, covers 57,666 shares at an exercise price of $3.70 per share, with an expiration date of August 10, 2036. The filing notes this transaction predates the company's initial public offering and is reported under Rule 16a-2(a).

The vesting schedule for the 57,666-share grant, as described in the filing, provides that the options "vest as to 1/48 of the total award monthly over four years, with the first tranche vested on August 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date." The second grant, dated October 22, 2026, covers 20,000 shares at an exercise price of $18.00 per share, expiring October 21, 2036. The filing states these options "will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date."

Both option grants are held directly by Henderson and were acquired at a recorded derivative security price of $0, according to the filing. No non-derivative securities transactions were reported in Table I. The Form 4 was signed by Amy Bachrodt as Attorney-in-Fact on October 26, 2026.

What Was Disclosed

Director Jane Henderson disclosed the acquisition of two stock option grants from Lycia Therapeutics, totaling 77,666 options on common stock. The grants carry exercise prices of $3.70 and $18.00 and follow separate vesting schedules as detailed in the filing's footnotes.